

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 February 2023 (16.02.2023)



(10) International Publication Number
WO 2023/019067 A1

(51) International Patent Classification:
C12N 15/113 (2010.01)

(21) International Application Number:
PCT/US2022/074307

(22) International Filing Date:
29 July 2022 (29.07.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/230,707 07 August 2021 (07.08.2021) US

(71) Applicants: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY** [CA/CA]; 845 Sherbrooke Street West, Office of Sponsored Research, James Admin. Bldg., Montreal, Québec H3A 0G4 (CA).

(72) Inventors: **BOVIJN, Jonas**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **SOSINA, Olukayode**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **ZHOU, Sirui**; 845 Sherbrooke Street West, Office of Sponsored Research, James Admin. Bldg., Montreal, Québec H3A 0G4 (CA). **LOTTA, Luca, Andrea**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **BARAS, Aris**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **RICHARDS, Brent**; 845 Sherbrooke Street West, Office of Sponsored Research, James Admin. Bldg., Montreal, Québec H3A 0G4 (CA).

(74) Agent: **LEGAARD, Paul, K.**; c/o Armstrong Teasdale LLP, 7700 Forsyth Blvd., Suite 1800, St. Louis, Missouri 63105 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

WO 2023/019067 A1

(54) Title: METHODS OF TREATING DECREASED BONE MINERAL DENSITY WITH CLUSTER OF DIFFERENTIATION 109 (CD109) INHIBITORS

(57) Abstract: The present disclosure provides methods of treating a subject having decreased bone mineral density or at risk of developing decreased bone mineral density, and methods of identifying subjects having an increased risk of developing decreased bone mineral density.